Skip to main content

Mortimer Ian's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed May 26, 2023

Accession no.
0000950170-23-024600
Filed
May 26, 2023
Trade date
May 24, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.31M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mortimer IanCIK 0001619961Director, Officer (PRESIDENT & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 24, 2023Common SharesMOption exerciseAcquired+42,592$9.44F1+$402,068.4848,592Direct
May 24, 2023Common SharesFTax withholdingDisposed−7,310$41.84F2−$305,850.441,282Direct
May 24, 2023Common SharesSSaleDisposed−17,069$41.44F3−$707,339.3624,213Direct
May 24, 2023Common SharesMOption exerciseAcquired+20,576$9.85F4+$202,673.644,789Direct
May 24, 2023Common SharesFTax withholdingDisposed−3,902$41.84F2−$163,259.6840,887Direct
May 24, 2023Common SharesSSaleDisposed−13,179$41.37F5−$545,215.2327,708Direct
May 24, 2023Common SharesMOption exerciseAcquired+6,172$9.85F4+$60,794.233,880Direct
May 24, 2023Common SharesFTax withholdingDisposed−1,171$41.84F2−$48,994.6432,709Direct
May 24, 2023Common SharesSSaleDisposed−1,407$41.49F6−$58,376.4331,302Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 24, 2023Common SharesMOption exerciseDisposed−42,592$0.00$00Direct
May 24, 2023Common SharesMOption exerciseDisposed−20,576$0.00$00Direct
May 24, 2023Common SharesMOption exerciseDisposed−6,172$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Referenced by the price of 1 transaction in Table I.

F2

Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations.

Referenced by the price of 3 transactions in Table I.

F3

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F4

The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Referenced by the price of 2 transactions in Table I.

F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F6

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)